Results 31 to 40 of about 399,504 (355)

JAK3 as an emerging target for topical treatment of inflammatory skin diseases [PDF]

, 2016
The recent interest and elucidation of the JAK/STAT signaling pathway created new targets for the treatment of inflammatory skin diseases (ISDs). JAK inhibitors in oral and topical formulations have shown beneficial results in psoriasis and alopecia ...
Alves de Medeiros, Ana, De Schepper, Sofie, Desmet, Eline, Lambert, Jo, Speeckaert, Reinhart, Van Gele, Mireille   +5 more
core   +14 more sources

A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs

Molecular & Cellular Oncology, 2021
While Janus-kinase (JAK)-inhibitors effectively reduce the inflammatory phenotype of myeloproliferative neoplasms (MPN), they do not affect disease burden or presence of the mutated clone to a major extent. Here, we show how Janus-kinase 2 (JAK2)-mutated
Tina M. Schnoeder, Florian Perner, Florian H. Heidel   +2 more
doaj   +1 more source

Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2

Journal of Translational Medicine, 2022
Background JAK1 and JAK2 have been implicated in fibrosis and cancer as a fibroblast-related marker; however, their role in liver fibrosis has not been elucidated.
Zhenghui Song, Xinhui Liu, Wan Zhang, Yue Luo, Hua Xiao, Yun Liu, Guanqi Dai, Jian Hong, Aimin Li   +8 more
doaj   +1 more source

In silico method potential therapeutic use of Janus Kinase inhibitors as severe acute respiratory syndrome coronavirus 2 main protease inhibitors

Journal of the Scientific Society, 2023
Background: Coronavirus disease 2019 (COVID-19), it is an infectious respiratory disease caused by SARS corona virus 2 (SARS CoV-2). There are several reports of using JAK (Janus kinase)-inhibitors in persons with COVID-19 and the use of these decreased ...
Shankar Gharge, Sushmita I Hiremath, Akshata S Menasinakai, Mahesh S Palled   +3 more
doaj   +1 more source

Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders

Pharmacological Research, 2022
The Janus kinase (JAK) family of nonreceptor protein-tyrosine kinases consists of JAK1, JAK2, JAK3, and TYK2 (Tyrosine Kinase 2). Each of these proteins contains a JAK homology pseudokinase (JH2) domain that interacts with and regulates the activity of ...
Robert Roskoski, Jr.
doaj   +1 more source

Overexpression of Janus kinase 2 protein in extramammary Paget’s disease [PDF]

Japanese Journal of Clinical Oncology, 2021
Abstract Extramammary Paget’s disease is a rare malignant tumor of the skin that occurs primarily in the genitocrural region. Although the prognosis of extramammary Paget’s disease with distant metastasis is poor, an effective therapy has not been established.
Saki, Otsuka-Maeda, Myangat Tselmeg, Mijiddorj, Ikko, Kajihara, Ryoko, Sakamoto, Saori, Yamada-Kanazawa, Hisashi, Kanemaru, Yuki, Nishimura, Soichiro, Sawamura, Katsunari, Makino, Jun, Aoi, Takamitsu, Makino, Shinichi, Masuguchi, Satoshi, Fukushima, Hironobu, Ihn   +13 more
openaire   +2 more sources

An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis

Haematologica, 2017
In most patients with primary myelofibrosis, one of three mutually exclusive somatic mutations is detected. In approximately 60% of patients, the Janus kinase 2 gene is mutated, in 20%, the calreticulin gene is mutated, and in 5%, the myeloproliferative ...
Uri Rozovski, Srdan Verstovsek, Taghi Manshouri, Vilma Dembitz, Ksenija Bozinovic, Kate Newberry, Ying Zhang, Joseph E. Bove, Sherry Pierce, Hagop Kantarjian, Zeev Estrov   +10 more
doaj   +1 more source

Janus Kinase 2 Influences Growth Hormone Receptor Metalloproteolysis [PDF]

Endocrinology, 2006
GH signals through the GH receptor (GHR), a cytokine receptor superfamily member that couples to the cytoplasmic tyrosine kinase, Janus kinase 2 (JAK2). In addition to its role in signaling, we recently implicated JAK2 in the regulation of cell surface GHR abundance by modulation of GHR trafficking and mature GHR stability.
Kimberly, Loesch, Luqin, Deng, Jon W, Cowan, Xiangdong, Wang, Kai, He, Jing, Jiang, Roy A, Black, Stuart J, Frank   +7 more
openaire   +2 more sources

Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]

, 2019
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran, Meier, Katharina, Solimani, Farzan   +2 more
core   +1 more source

Pharmacology of inhibitors of Janus kinases – Part 2: Pharmacodynamics

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2022
SummaryAs small molecules, the Janus kinase inhibitors have different, dose‐dependent pharmacological binding selectivities, which, however, do not allow reliable statements about the clinical specificity of desired or side effects. It is therefore of particular importance to recognize that the pharmacodynamics of the individual Janus kinase inhibitors
Adina, Eichner, Johannes, Wohlrab
openaire   +2 more sources